In ccRCC, METTL3 enhances glucose uptake and lactate accumulation by catalyzing the m6A modification of GLUT1 mRNA, stabilizing its transcript and activating mTORC signaling, which drives resistance to mTOR inhibitors [114]. The gene discussed is SLC2A1; the disease is nonpapillary renal cell carcinoma.